With　the　successful　use　of　gefitinib　and　erlotinib　in　clinic,　some　potent　EGFR　tyrosine　kinase　receptor　inhibitors　have　gained　widespread　concern　in　the　treatment　of　ovarian　or　non-small-cell　lung　cancer.　However,　the　emergence　of　EGFR-activating　mutations　resist　to　the　drugs,　there　is　an　impending　need　to　design　new　inhibitor　targeted　EGFR.　Furthermore,　the　understanding　of　mutual　effect　between　EGFR　and　drug　has　been　available,　it　has　become　a　hot　spot　for　the　research　of　anticancer　drugs.　We　have　designed　and　synthesized　a　series　of　6-methoxy-7-(3-morpholinopropoxy)-1-(2-phenoxyethyl)-quinoxalin-2(1H)-one　derivatives　as　novel　EGFR　inhibitors.　Most　of　the　compounds　have　showed　inhibitory　activity　toward　EGFR　kinase.　This　work　has　demonstrated　it　is　possible　to　construct　a　new　type　of　EGFR　protein　kinase　inhibitor　using　a　design-in　strategy.